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Abstract 
SIRT1 is a member of the mammalian sirtuin genes 
that encode for seven protein lysine modifiers with 
deacetylase, ADP-ribosyltransferase and other 
deacylase activities. SIRT1 plays diverse roles in 
regulating cell proliferation, differentiation, stress 
response, metabolism, energy homeostasis, aging 
and cancer. Besides deacetylating histone substrates, 
SIRT1 regulates functions of an array of non-histone 
proteins including transcriptional factors for gene 
regulation, DNA repair machinery elements for 
reducing catastrophic genome lesions, epigenetic 
factors for chromatin and gene regulation, nuclear 
receptors and circadian clock as well as related 
factors for metabolism, and other cell signaling 
molecules. SIRT1 is involved in many types of 
human cancer. 
Identity 
Other names: EC 3.5.1, hSIR2, hSIRT1, 
SIR2alpha, SIR2L1 
HGNC (Hugo): SIRT1 
Location: 10q21.3 
DNA/RNA 
Description 
The SIRT1 gene spans about 34 kb including nine 
exons. The SIRT1 promoter contains a CCAAT box 
and a number of NF-kappaB and GATA 
transcription factor binding sites in addition to a 
small 350-bp CpG island in the 5' flanking genomic 
region.  
The gene encodes a 747 amino acids protein with a 
predictive molecular weight of 81.7 kDa and an 
isoelectric point of 4.55 (Alcaín and Villalba, 2009). 
Transcription 
SIRT1 transcription is under the control of at least 
two negative feedback loops that keep its induction 
tightly regulated under conditions of oxidative 
stress.  
SIRT1 promoter can be regulated by E2F1 and HIC1 
during cellular stress. E2F1 directly binds to the 
SIRT1 promoter at a consensus site located at bp 
position -65 and appears to regulate the basal 
expression level of SIRT1. Such high levels of 
SIRT1 lead to a negative feedback loop where E2F1 
activity is inhibited by SIRT1-mediated 
deacetylation. By contrast, the tumor suppressor 
HIC1 and SIRT1 form a transcriptional repression 
complex that directly binds SIRT1 promoter and 
represses SIRT1 transcription thereby inhibiting 
SIRT1-mediated p53 deacetylation and inactivation. 
Two HIC1 binding sites have been assigned to base 
pair positions -1116 and -1039 within the SIRT1 
promoter (Chen et al., 2005). In addition, two 
functional p53 binding sites (-178 bp and -168 bp), 
which normally repress SIRT1 expression, have 
been identified.  
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SIRT1 gene expression is modulated at both transcriptional and posttranscriptional levels. 
 
Furthermore, SIRT1 transcription is upregulated by 
MYC that binds at SIRT1 promoter position -80 and 
by STAT5 that binds at positions -2235 and -1838 in 
response to BCR-ABL oncogenic stress (Yuan et al., 
2012). 
SIRT1 expression is also regulated at the 
posttranscriptional level by HuR. It has been 
demonstrated that HuR, a ubiquitously expressed 
RNA binding protein, associates with the 3' UTR of 
the SIRT1 mRNA under physiological conditions 
and helps to stabilize the transcript. This interaction 
results in increased SIRT1 mRNA stability and thus 
in elevated protein levels. Conversely, the HuR-
SIRT1 mRNA complex is being disrupted upon 
oxidative stress, which finally leads to decreased 
mRNA stability and therefore decreased SIRT 
protein levels. In addition, several microRNA (miR) 
species negatively regulate SIRT1 mRNA by 
targeting its 3' UTR, including miR-34a and miR-
200a (reviewed in Roth and Chen, 2014). 
Pseudogene 
None identified. 
Protein 
Description 
Human SIRT1 encodes 747 amino acids protein with 
a nuclear localization signal (NLS) at the N-terminus 
(aa 41-46) and a sirtuin homology domain at the 
center (aa 261-447); this domain is a conserved 
catalytic domain for deacetylation. The catalytic 
activity of SIRT1 is dependent on the cofactor 
nicotinamide adenine dinucleotide (NAD+). 
Expression 
Expression appears to be ubiquitous in adult tissues  
 
(although at different levels).  
Two proteins have been identified to regulate the 
SIRT1 activity both positively and negatively 
through complex formation in the context of the 
cellular stress response.  
The first identified direct regulator of SIRT1 was the 
active regulator of SIRT1 (AROS).  
The AROS protein is known to significantly enhance 
the activity of SIRT1 on acetylated p53 both in vitro 
and in cell lines thereby promoting the inhibitory 
effect of SIRT1 on p53-mediated transcriptional 
activity of pro-apoptotic genes (e.g. Bax and 
p21Waf-1) under conditions of DNA-damage. A 
negative regulator of SIRT1, DBC-1 (deleted in 
breast cancer-1), has recently been identified. DBC1 
binds directly to the catalytic domain of SIRT1, 
preventing substrate binding to SIRT1 and inhibiting 
SIRT1 activity.  
Reduction of DBC1 inhibits p53-mediated apoptosis 
after induction of double-stranded DNA breaks 
owing to SIRT1-mediated p53 deacetylation. Both 
factors represent the first endogenous, direct 
regulators of SIRT1 function. SIRT1 activity is also 
regulated by cis-elements of its own peptides. The 
SIRT1 C-terminal region (aa 631-635) is a 
disordered domain, and it interacts with SIRT1 
catalytic core domain by competing with DBC1 and 
activates SIRT1 activity (Kang et al., 2011). A small 
rigid region at the N-terminus (aa 190-244) of SIRT1 
appears to mediates allosteric activators for the 
SIRT1 catalytic core function (Hubbard et al., 2013).  
In addition, SIRT1 activity is subjected to regulation 
by other posttranslational modifications such as 
sumoylation, phosphorylation and methylation in 
response to stress signaling and cell cycle changes 
(reviewed in Wang and Chen, 2013).  
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SIRT1 deacetylase activity is modulated through protein-protein interaction and sumoylation at its three protein domains (Liu T et 
al., 2009). 
 
As an NAD-dependent enzyme, SIRT1 activity is 
regulated by cellular NAD metabolism in which 
NAD salvage pathway enzyme nicotinamide 
phosphoribosyltransferase (NAMPT) is often co-
activated with SIRT1 to maintain the deacetylase 
activity (Wang et al., 2011; Menssen et al., 2012). 
Localisation 
SIRT1 is predominately in the nucleus (although 
SIRT1 does have some important cytoplasmic 
functions as well). In addition to possessing two 
NLSs, SIRT1 contains two nuclear export signals. 
Thus, the exposure of nuclear localization signals 
versus nuclear export signals may dictate the 
cytosolic versus nuclear localization of SIRT1. 
Function 
SIRT1 has been reported to play a key role in a 
variety of physiological processes such as 
metabolism, neurogenesis and cell survival due to its 
ability to deacetylate both histone and numerous 
nonhistone substrates. 
(1) Lysines 9 and 14 in the amino-terminal tail of 
histone H3 and lysine 16 of histone H4 are 
deacetylated by yeast Sir2 and mammalian SIRT1 
(Sir2alpha). 
(2) Metabolic homeostasis is controlled by SIRT1-
mediated deacetylation and thus activation of the 
peroxisome proliferation activating receptor 
(PPAR)-gamma co-activator-1a (PGC-1a), which 
stimulates mitochondrial activity and subsequently 
increases glucose metabolism, which in turn 
improves insulin sensitivity. SIRT1 represses PPAR-
gamma, a key regulator of adipogenesis, by docking 
with its cofactors NCoR (nuclear receptor co-
repressor) and SMRT (silencing mediator of retinoid 
and thyroid hormone receptors). The upregulation of 
SIRT1 triggers lipolysis and loss of fat. 
(3) The activation of SIRT1 appears to be 
neuroprotective in animal models for Alzheimer's 
disease and amyotrophic lateral sclerosis as well as 
optic neuritis mainly due to decreased deacetylation 
of the tumor suppressor p53 and PGC-1a. 
(4) SIRT1 represses p53-dependent apoptosis in 
response to DNA damage and oxidative stress and 
promotes cell survival under cellular stress induced 
by etoposide treatment or irradiation. 
(5) SIRT1 activates FOXO1 and FOXO4, which 
promote cell-cycle arrest by inducing p27kip1; 
SIRT1 also induces cellular resistance to oxidative 
stress by increasing the levels of manganese 
superoxide dismutase and GADD45 (growth arrest 
and DNA damage-inducible protein 45). 
(6) SIRT1 inhibits the transcriptional activity of NF-
kappaB by deacetylating NF-kappaB's subunit, 
RelA/p65, at lysine 310. Thus, although SIRT1 is 
capable of protecting cells from p53-induced 
apoptosis, it may augment apoptosis by repressing 
NF-kappaB. SIRT1 is reported to bind CTIP2 
(BCL11B B-cell CLL/lymphoma 11B) and 
accelerate the transcriptional repression by this 
molecule. CTIP2 represses the transcription of its 
target genes and is implicated in hematopoietic cell 
development. 
(7) SIRT1 deacetylates and activates functions of 
several DNA repair factors, including KU70, NBS1, 
APE1, XPA/C and WRN for multiple DNA damage 
repair pathways to cope with genotoxic stress. 
Stimulated repair may help cells avoid catastrophic 
genomic events and survive the damage. 
(8) SIRT1 is involved in epigenetic regulation of 
genes and chromatin. SIRT1 deacetylates several 
histone tail lysines: histone H4 lysine 16 (H4K16), 
histone H3 K9 and K14, and histone H1 K26. These 
modifications of histone tails are closely related to 
gene silencing and heterochromatin formation that 
may underlie certain biological processes. SIRT1 
can deacetylate DNA methyltransferase 1 (DNMT1) 
and can either enhance or hinder its 
methyltransferase activity, thus indirectly affecting 
global or local DNA methylation patterns.  
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SIRT1 is a component of the polycomb repressor 
complex (PRC) that is involved in silencing genes 
during normal development.  
SIRT1 directly complexes with EZH2, a H3K27 
methyltransferase within PRC II complex, and is an 
integral part of the PRC's silencing functions. A 
SIRT1-containing PRC complex, termed PRC4, is 
specifically found in transformed cells and 
embryonic stem cells.  
In addition, SIRT1 interacts and deacetylates the 
SUV39H1 methyltransferase, promoting histone H3 
methylation and fostering heterochromatin 
formation, and repressing rRNA transcription to 
protect cells from energy deprivation-dependent 
apoptosis (reviewed in Roth and Chen, 2014). 
Homology 
SIRT1 is the mammalian homologue closest to yeast 
NAD+-dependent deacetylase Sir2 (silent 
information regulation 2).  
It was originally identified as a lifespan extending 
gene when over-expressed in budding yeast, 
Caenorhabditis elegans, and Drosophila 
melanogaster. The SIR2 gene is broadly conserved 
in organisms ranging from bacteria to humans. The 
accession numbers for the amino acid sequences 
used are as follows: yeast Sir2 (CAA25667), mouse 
Sir2alpha (AAF24983), human Sirt1 (AAD40849). 
All of the sirtuin proteins contain the ~275 residue 
sirtuin homology domain. In many instances a highly 
conserved protein domain represents a conserved 
functional binding site for a metabolite or 
biomolecule and such conserved binding site 
domains are often found within enzymatic catalytic 
domains. 
Mutations 
Germinal 
A germ line mutation L107P of SIRT1 was found in 
a family with type I diabetes. Expression of this 
mutant SIRT1 in insulin-producing cells stimulated 
production of nitric oxide, cytokines and 
chemokines, and decreased anti-inflammatory 
activity of pancreatic beta cells (Biason-Lauber et 
al., 2013). 
Somatic 
A small number of SIRT1 somatic mutations were 
registered in human cancer databases but the 
mutation rate is typically very low (<0.5%) and their 
effect on SIRT1 function is unknown. Both gene 
amplification and deletion are found in human 
cancers depending on cancer types (reviewed in 
Roth and Chen, 2014). 
Implicated in 
Chronic myelogenous leukemia 
SIRT1 plays an important role in drug resistance of 
chronic myelogenous leukemia (CML). 
Disease 
CML is a lethal malignant disease of hematopoietic 
stem cells. It is caused by reciprocal translocation of 
chromosomes 9 and 22, producing BCR-ABL fusion 
gene. BCR-ABL protein has aberrant tyrosine kinase 
activity and predominantly resides in the cytoplasm 
in contrast to predominantly nuclear localization of 
ABL protein. CML progresses from chronic phase to 
accelerated phase and blast crisis with increasing 
numbers of blast cells in bone marrow and blood. 
SIRT1 is activated by BCR-ABL oncogenic 
transformation in human CML stem/progenitor cells 
(Yuan et al., 2012; Li et al., 2012). 
Prognosis 
CML in chronic phase can be effectively treated 
tyrosine kinase inhibitors such as first-line drug 
imatinib, and second-line drugs nilotinb and 
dasatinib, which results in the five-year survival rate 
over 85%. However, the residual disease persists as 
these drugs do not eradicate CML leukemic stem 
cells, and the disease relapses if the drug is ceased. 
CML in advanced phases has much poorer prognosis 
and the disease typically relapses quickly on tyrosine 
kinase inhibitor treatment since the cells acquire 
BCR-ABL mutations that block the binding of the 
drugs to BCR-ABL. 
Cytogenetics 
Philadelphia chromosome, t(9;22) translocation. 
Abnormal protein 
BCR-ABL fusion protein with aberrant tyrosine 
kinase activity. 
Oncogenesis 
BCR-ABL transformation activates SIRT1 gene 
expression in both tyrosine kinase-dependent and 
independent manners, with the former mediating via 
STAT5 that binds on the SIRT1 promoter to 
stimulate the transcription. The mechanism for the 
kinase-independent SIRT1 activation is unknown. 
SIRT1 knockout significantly blocks BCR-ABL 
mediated leukemogenesis in a mouse model study 
(Yuan et al., 2012). Since blocking BCR-ABL 
kinase activity only partially reduces SIRT1 
expression and the pathway remains active, SIRT1 
inhibition sensitizes human CML leukemia stem 
cells to tyrosine kinase inhibitors and helps eradicate 
these cells by increasing p53 acetylation and 
activating p53 downstream target gene expression 
(Li et al., 2012). In addition, SIRT1 promotes 
acquisition of resistant BCR-ABL mutations for 
disease relapse in association with its ability to 
deacetylate and activate KU70 for increased error-
prone DNA damage repair in blast crisis CML cells 
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(Wang et al., 2013). Targeting SIRT1 may have 
clinical implication to improve CML treatment. 
Acute myeloid leukemia 
SIRT1 plays an important role in drug resistance of 
acute myeloid leukemia (AML) with FLT-ITD 
mutation. 
Disease 
AML is a group of highly heterogenous myeloid 
leukemia with distinct oncogenic events including 
various chromosomal aberrations and mutations. 
AML is generally derived from myeloid progenitor 
cells. SIRT1 protein expression is more consistently 
increased in AML samples, particularly those 
harboring FLT-ITD alteration. The change of SIRT1 
mRNA is less consistent in certain AML 
subcategories from one to another study (Sasca et al., 
2014; Li et al., 2014). 
Prognosis 
AML with FLT-ITD mutation has poor prognosis. 
Abnormal protein 
FLT-ITD has constitutively activated tyrosine kinase 
activity. 
Oncogenesis 
Similar to BCR-ABL transformation of 
hematopoietic stem cells, SIRT1 expression change 
in AML cells is likely a result of cellular response to 
oncogenic stress. However, protein regulation of 
SIRT1 appears more important in the AML setting. 
SIRT1 protein is stabilized by USP22, a 
deubiquitinase that is induced by c-MYC in FLT-
ITD AML cells (Li et al., 2014). In addition, SIRT1 
activity is further regulated by ATM-DBC1 in a 
FLT-ITD dependent manner (Sasca et al., 2014). 
Inhibition of SIRT1 sensitizes FLT-ITD AML 
stem/progenitor cells to tyrosine kinase inhibitor 
treatment, and may help improve management of 
this category of AML. 
Lymphoma 
In large B-cell lymphoma patients, positive 
expression of SIRT1 protein was seen in 74% of 
patients, and significantly associated with shorter 
overall survival. Inhibition of SIRT1/2 by Cambinol 
induces apoptosis in Burkitt lymphoma cells 
(reviewed in Yuan et al., 2013). 
Prognosis 
Large B-cell lymphoma with SIRT1 upregulation 
showed poor prognosis. 
Lung cancer 
Distinct status of p53 acetylation/deacetylation and 
HIC1 alteration mechanism result from different 
SIRT1-DBC1 (deleted in breast cancer 1) control 
and epigenetic alteration in lung squamous cell 
carcinoma and lung adenocarcinoma. The lung 
squamous cell carcinoma patients with low p53 
acetylation and SIRT1 expression mostly showed 
low HIC1 expression, confirming deregulation 
HIC1-SIRT1-p53 circular loop in clinical model. 
Expression of DBC1, which blocks the interaction 
between SIRT1 deacetylase and p53, led to 
acetylated p53 in lung adenocarcinoma patients. 
Prognosis 
Lung cancer patients with altered HIC1-SIRT1-p53 
circular regulation showed poor prognosis. 
Breast cancer 
The breast cancer associated protein, BCA3, when 
neddylated (modified by NEDD8) interacts with 
SIRT1 and suppresses NF-kB-dependent 
transcription, also sensitizes human breast cancer 
cells (such as MCF7) to TNF-a-induced apoptosis. 
In addition, it has been shown recently that SIRT7 
levels of expression increase significantly in breast 
cancer, and that SIRT7 and SIRT3 both are highly 
transcribed in lymph-node positive breast biopsies, a 
stage in which the tumour size is at least 2 mm and 
the cancer has already spread to the lymph nodes. 
SIRT1 up-regulation is also associated with 
decreased miR-200a in breast cancer samples, which 
targets the 3'UTR of SIRT1 mRNA and promotes 
epithelial-mesenchymal transition (EMT)-like 
transformation in mammary epithelial cells. SIRT1 
is essential for oncogenic signaling of 
estrogen/estrogen receptor α (ERα) in breast cancer. 
SIRT1 inactivation suppresses estrogen/ERα-
induced cell growth and tumor development, and 
induces apoptosis. SIRT1 is found to be significantly 
up-regulated in the invasive ductal carcinoma, and 
positively regulates the expression of aromatase, an 
enzyme responsible for a key step in the biosynthesis 
of estrogen in breast cancer. However, in HMLER 
breast cancer cells, SIRT1 was found to suppress 
EMT, and reduced SIRT1 expression increases 
metastasis of these cells in nude mice (reviewed in 
Yuan et al., 2013). 
Prostate cancer 
SIRT1 is significantly overexpressed in primary 
human prostate cancer tissues and cell lines. SIRT1 
inhibition via nicotinamide, sirtinol, short hairpin 
RNAs or mutation of the 25 amino acid C-terminal 
SIRT1 activator sequence, results in a significant 
inhibition of prostate cancer cell growth, viability 
and chemoresistance. SIRT1 is highly expressed in 
advanced prostate cancer tissues and promotes 
prostate cancer cell invasion, migration and 
metastasis through MMP2, EMT inducing 
transcription factor ZEB1, and cortactin. 
Concomitant with SIRT1 activation, NAMPT is 
over-expressed in prostate cancer, likely enabling 
supply of NAD+ for SIRT1 functions. In the 
transgenic mouse model, SIRT1 expression 
promotes murine prostate carcinogenesis initiated by 
Pten-deficiency (reviewed in Yuan et al., 2013). 
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Liver cancer 
SIRT1 expression is significantly elevated in 
hepatocellular carcinoma (HCC) tissues, and the 
expression levels correlate with tumor grades and 
predict poor prognosis. SIRT1 expression also 
positively correlates with c-MYC levels in HCC. 
SIRT1 and c-MYC regulate each other via a positive 
feedback loop and act synergistically to promote cell 
proliferation of both mouse and human liver tumor 
cells. SIRT1 promotes tumorigenesis and 
chemoresistance in HCC, and inhibition of SIRT1 
suppresses the proliferation of HCC cells in vitro or 
in vivo via the induction of cellular senescence or 
apoptosis. Accordingly, expression of miRNA-34a 
is reduced in HCC, and the reduced expression of 
miRNA-34a is associated with worse outcome of 
HCC patients. Treatment of established HCC 
xenograft with miR-34a-expressing adenovirus in a 
mouse model results in complete tumor regression 
without recurrence (reviewed in Yuan et al., 2013). 
Gastric cancer 
SIRT1 protein expression in gastric cardiac 
carcinoma is significantly higher than that in normal 
gastric tissues and is associated with lymphatic 
metastasis, TNM [the extent of tumor (T), the extent 
of spread to lymph nodes (N), and the presence of 
distant metastasis (M)] stage, survival rate and mean 
survival time. In another study, positive expression 
of SIRT1 was seen in 73% of gastric cancer patients. 
SIRT1 expression is also significantly associated 
with shorter overall survival and relapse-free 
survival. SIRT1 is required for activating 
transcription factor 4 (ATF4)-induced multidrug 
resistance in gastric cancer cells. ATF4 facilitates 
multidrug resistance in gastric cancer cells through 
direct binding to SIRT1 promoter and activating 
SIRT1 expression. Significantly, inhibition of 
SIRT1 by RNAi or a specific inhibitor (EX-527) 
sensitizes gastric cancer cells to therapeutic 
treatment (reviewed in Yuan et al., 2013). 
Pancreatic cancer 
SIRT1 overexpression was observed in pancreatic 
cancer tissues at both mRNA and protein levels. 
Increased SIRT1 positivity is associated with 
patients' age (over 60 years old), larger tumor size 
(larger than 4 cm), and higher TNM stage. SIRT1 
knockdown induces apoptosis and senescence, 
inhibits invasion and enhances chemosensitivity in 
pancreatic cancer cells. In pancreatic cancer, SIRT1 
regulates ADM (acinar-to-ductal metaplasia) and 
supports cancer cell viability through deacetylating 
pancreatic transcription factor-1a and β-catenin. 
Inhibition of SIRT1 is effective in suppression of 
ADM and in reducing cell viability in established 
pancreatic ductal adenocarcinoma. In addition, 
SIRT1 promotes EMT ability as well as invasion of 
pancreatic cancer cell by forming a complex with 
Twist and MBD1 thus suppressing E-cadherin 
transcription activity. However, one study showed 
that SIRT1 inhibits proliferation of pancreatic cancer 
cells expressing oncogenic pancreatic 
adenocarcinoma up-regulated factor (PAUF), by 
suppression of β-catenin and cyclin-D1 (reviewed in 
Yuan et al., 2013). 
Thyroid cancer 
SIRT1 is overexpressed in human thyroid cancers 
and it is positively correlated with c-MYC protein 
levels. Transgenic SIRT1 expression promotes 
murine thyroid carcinogenesis initiated by Pten-
deficiency. SIRT1 increases c-MYC transcription 
and stabilizes c-MYC protein in thyroid cancers 
from SIRT1 transgenic mice or cultured thyroid 
cancer cells (reviewed in Yuan et al., 2013). 
Colon cancer 
Highly-expressed c-MYC correlates with increased 
SIRT1 protein level in colorectal cancer.  
In 121 colorectal serrated lesions, the higher 
expression of c-MYC and SIRT1 protein is strongly 
associated with higher grades of malignancy. In 
another study with a total of 485 colorectal cancer 
patients, SIRT1 overexpression was detected in 180 
(37%) tumors.  
SIRT1 expression is associated with microsatellite 
instability and CpG island methylator phenotype, 
although not patient prognosis. Reduced expression 
of miR-34a, a negative regulator of SIRT1 mRNA, 
is observed in drug-resistant DLD-1 colon cancer 
cells, and introduction of miR-34a induces apoptosis 
by downregulating SIRT1. However, one study 
showed that in colorectal adenocarcinoma, SIRT1 
overexpression was observed in approximately 25% 
of stage I/II/III tumors but rarely in advanced stage 
IV tumors. Approximately 30% of carcinomas 
showed lower SIRT1 expression than normal tissues. 
In another clinical observation, SIRT1 protein 
expression is gradually decreased during the normal-
adenoma-adenocarcinoma-metastasis stage in 
colorectal cancers, with the positivity 100%, 80.8%, 
41.9%, and 35.7%, respectively (reviewed in Yuan 
et al., 2013). 
Ovarian cancer 
Expression of SIRT1 protein is significantly 
increased in malignant ovarian epithelial tumors 
compared to that in benign and borderline epithelial 
tumors. High proportion (86%) of serous ovarian 
cancer expressed SIRT1. Interestingly, increased 
SIRT1 protein in serous ovarian epithelial cancer 
was associated with increased overall survival (Jang 
et al., 2009). 
Brain tumor 
In glioblastoma, SIRT1 is highly expressed in tumor-
derived CD133+ progenitor cells compared to 
CD133-cells and knockdown of SIRT1 expression 
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enhances the radio-sensitivity and radiation-induced 
apoptosis in the CD133+ cells. SIRT1 is also 
frequently expressed in human medulloblastomas 
relative to surrounding noncancerous cerebellar 
tissues and its expression is correlated with the 
formation and prognosis of medulloblastomas. 
SIRT1 and N-MYC form a positive feedback 
regulation loop during the tumorigenesis of 
neuroblastoma, and preventive treatment with the 
SIRT1 inhibitor Cambinol significantly reduces 
tumorigenesis in N-MYC transgenic mice (reviewed 
in Yuan et al., 2013). 
Soft tissue sarcoma 
SIRT1 is frequently over-expressed in soft tissue 
neoplasms with myoid differentiation including 
angiomyolipoma (4 out of 4 patients), glomus tumor 
(5 out of 5 patients), leiomyoma (9 out of 10 
patients), leiomyosarcoma (76.5% of 51 patients), 
and rhabdomyosarcoma (87% of 24 patients), and 
thus could be a potential immunohistochemical 
marker and therapeutic target in these tumors 
(reviewed in Yuan et al., 2013). 
Kidney diseases 
SIRT1 attenuates TGF-beta (transforming growth 
factor-beta) apoptotic signaling that is mediated by 
the effector molecule Smad7. SIRT1-dependent 
deacetylation of Smad7 at Lys60 and Lys70 
enhances its ubiquitin-dependent proteasomal 
degradation via Smurf1 (Smad ubiquitination 
regulatory factor 1), thus protecting glomerular 
mesangial cells from TGF-beta-dependent 
apoptosis. As a result, SIRT1 expression tends to 
have protective roles in diabetic kidney disease and 
excessive inflammatory response triggered by 
bacterial endotoxins. However, SIRT1 inhibition 
was found to delay kidney cyst formation in 
autosomal-dominant polycystic kidney disease 
through regulating Rb and p53 in cystic renal 
epithelial cells (Zhou et al., 2013). 
Cardiac hypertrophy 
Decreasing hypertrophy or apoptosis in cardiac 
myocytes can ameliorate the disease, and there is 
reason to suspect that SIRT1 activation may be 
useful in this regard. SIRT1 protects primary 
cultured myocytes from programmed cell death 
induced by serum starvation or by the activation of 
PARP-1 [poly(ADP-ribose) polymerase-1] in a p53-
dependent manner. SIRT1 also deacetylates Lys115 
and Lys121 of the histone variant H2A.Z, a factor 
known to promote cardiac hypertrophy. In doing so, 
SIRT1 promotes the ubiquitination and proteosome-
dependent degradation of H2A.Z, which may help to 
protect against heart failure. However, in mouse 
models it was found that SIRT1 haploinsufficiency 
attenuates pressure overload-induced cardiac 
hypertrophy and heart failure (Oka et al., 2011). 
Contributing to this effect, SIRT1, coordinated by 
PPARα, suppresses genes involved in mitochondrial 
functions. In a separate study, cardiac hypertrophy is 
reduced in Sirt1 deficient mice in response to 
physical exercise and angiotensin II due to impaired 
Akt activation as a result of its acetylation 
(Sundaresan et al., 2011). 
Breakpoints 
No breakpoints are associated with SIRT1. 
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